Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Celiac Disease D002446 16 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Intracranial Embolism and Thrombosis D002542 5 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Chediak-Higashi Syndrome D002609 4 associated lipids
Chest Pain D002637 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Kallmann R et al. Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects. 1987 Thromb. Res. pmid:3576521
Filep J and Rosenkranz B Mechanism of vasopressin-induced platelet aggregation. 1987 Thromb. Res. pmid:3105115
Ushiyama S et al. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. 1988 Thromb. Res. pmid:3175990
Svensson J and Samuelsson K Inhibition of platelet function by low dose acetylsalicylic acid in patients with cerebrovascular disease. 1983 Thromb. Res. pmid:20218005
Takasaki W et al. Superiority of plasma 11-dehydro-TXB2 to TXB2 as an index of in vivo TX formation in rabbits after dosing of CS-518, a TX synthase inhibitor. 1993 Thromb. Res. pmid:8367836
Kosaki G et al. The mechanism of the inhibitory effect of protease inhibitors on platelet aggregation and cellular synthesis of prostaglandins. I. The effect on the release of arachidonic acid from phospholipids. 1980 Dec 1-15 Thromb. Res. pmid:6785893
Anfossi G et al. Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood. 1995 Thromb. Res. pmid:7778055
Lee GY et al. Antiplatelet activity of BRX-018, (6aS,cis)-malonic acid 3-acetoxy-6a9-bis-(2-methoxycarbonyl-acetoxy)-6,6a,7,11b-tetrahydro-indeno[2,1-c]chromen-10-yl ester methylester. 2005 Thromb. Res. pmid:15668191
Ljungberg B et al. Immediate effects of heparin and LMW heparin on some platelet and endothelial derived factors. 1988 Thromb. Res. pmid:2847353
Boyd JA and Eling TE Prostaglandin release and the interaction of platelets with the pulmonary vasculature of rat and guinea pig. 1980 Jul 1-15 Thromb. Res. pmid:7003800
Mikashima H and Muramoto Y Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. 1990 Thromb. Res. pmid:2326771
Pedersen AK et al. Inhibition of thromboxane biosynthesis in serum: limitations of the measurement of immunoreactive 6-keto-PGF1 alpha. 1984 Thromb. Res. pmid:6546456
Pekonen F et al. Platelet function and coagulation in normal and preeclamptic pregnancy. 1986 Thromb. Res. pmid:2944245
Saldeen P et al. Thromboxane production in umbilical vein grafts. 1984 Thromb. Res. pmid:6546814
Chou TC and Li CY Inhibitory mechanisms of dantrolene on platelet aggregation. 1999 Thromb. Res. pmid:10593433
Davì G et al. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. 1982 Thromb. Res. pmid:6761893
Cerskus AL et al. Effects of indomethacin and sulfinpyrazone on in vivo formation of thromboxane B2 and prostaglandin D2 during arachidonate infusion in rabbits. 1978 Thromb. Res. pmid:653641
Rousson D et al. Acute myocardial infarction: measurement of arachidonate end-products in whole blood as an index of platelet cyclo-oxygenase activity in vivo. 1987 Thromb. Res. pmid:3122356
Cerskus AL et al. Thromboxane B2 and 6-keto-prostaglandin F1 alpha synthesis during infusion of collagen and arachidonic acid in rabbits: inhibition by aspirin and sulfinpyrazone. 1980 Thromb. Res. pmid:7414555
Rostagno C et al. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. 1991 Thromb. Res. pmid:1754998
Castaldi PA et al. Evidence for a platelet membrane defect in the myeloproliferative syndromes. 1982 Thromb. Res. pmid:6960545
Fitzpatrick F et al. Development of a gas chromatographic-mass spectrometric method using a stable isotope internal standard for quantitation of thromboxane B2. 1984 Thromb. Res. pmid:6474413
Kankuri E et al. Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. 2003 Thromb. Res. pmid:14592552
Davis RB et al. Evaluation of platelet function in pregnancy. Comparative studies in non-smokers and smokers. 1987 Thromb. Res. pmid:2955542
Catella F and FitzGerald GA Paired analysis of urinary thromboxane B2 metabolites in humans. 1987 Thromb. Res. pmid:3686481
Vericel E et al. Platelets and aging. I--Aggregation, arachidonate metabolism and antioxidant status. 1988 Thromb. Res. pmid:3129819
Arruzazabala ML et al. Effects of Policosanol on platelet aggregation in rats. 1993 Thromb. Res. pmid:8475481
Reis F et al. The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. 1999 Thromb. Res. pmid:10605951
Riess H et al. Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease. 1984 Thromb. Res. pmid:6237460
Cattaneo M et al. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. 1991 Thromb. Res. pmid:1926062
Patrono C et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. 1980 Feb 1-15 Thromb. Res. pmid:7368167
Koh H et al. A radioimmunoassay of thromboxane B2 with thromboxane B2-125I-tyramide and its application to the study on the thromboxane B2 formation during platelet aggregation. 1980 Feb 1-15 Thromb. Res. pmid:7368170
Kohda N et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. 1999 Thromb. Res. pmid:10593428
Winther K et al. Platelet function and fibrinolytic activity in cervical spinal cord injured patients. 1992 Thromb. Res. pmid:1321515
Chetty N and Bradlow BA The effects of a vegetarian diet on platelet function and fatty acids. 1983 Thromb. Res. pmid:6612688
Lee TK et al. Comparison of the effect of acetylsalicylic acid on platelet function in male and female patients with ischemic stroke. 1987 Thromb. Res. pmid:3629557
Tanoue K et al. A new variant of thrombasthenia with abnormally glycosylated GP IIb/IIIa. 1987 Thromb. Res. pmid:3629560
Franconi F et al. Effect of gamma-hydroxybutyric acid on human platelet aggregation in vitro. 2001 Thromb. Res. pmid:11369419
Petroni A et al. Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. 1995 Thromb. Res. pmid:7482432
De La Cruz JP et al. Antithrombotic potential of olive oil administration in rabbits with elevated cholesterol. 2000 Thromb. Res. pmid:11113274
Barnhart MI et al. DDAVP: does the drug have a direct effect on the vessel wall? 1983 Thromb. Res. pmid:6415852
Davì G et al. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs. 1985 Thromb. Res. pmid:2933846
Saldeen P and Saldeen T 6-keto-prostaglandin F1 alpha/thromboxane B2 ratio in vascular and lung tissue. 1983 Thromb. Res. pmid:6688484
Sandler H et al. Studies on the role of thromboxane in thrombin-induced pulmonary insufficiency in the rat. 1986 Thromb. Res. pmid:3754987
Di Minno MN et al. Genotype-independent in vivo oxidative stress following a methionine loading test: maximal platelet activation in subjects with early-onset thrombosis. 2011 Thromb. Res. pmid:21669453
Lagarde M et al. Increase of platelet thromboxane A2 formation and of its plasmatic half-life in diabetes mellitus. 1980 Thromb. Res. pmid:7466751
McGill D et al. Platelet function and exercise-induced myocardial ischaemia in coronary heart disease patients. 1989 Thromb. Res. pmid:2533414
Li C et al. Aspirin response variability after major orthopedic surgery. 2012 Thromb. Res. pmid:22575418
Takasaki W et al. Enzyme immunoassay of human plasma 11-dehydrothromboxane B2. 1991 Thromb. Res. pmid:1957275
Toft G et al. Intravenously and topically applied magnesium in the prevention of arterial thrombosis. 2000 Thromb. Res. pmid:10904104
Schmid P et al. Passive smoking and platelet thromboxane. 1996 Thromb. Res. pmid:8907294
Riess H et al. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients. 1986 Thromb. Res. pmid:3012819
Pirich C et al. Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. 1999 Thromb. Res. pmid:10588465
Altman R et al. Synergistic actions of PAF-acether and sodium arachidonate in human platelet aggregation. 1. Studies in normal human platelet rich plasma. 1986 Thromb. Res. pmid:3014677
Yamaguchi A et al. Effect of cetiedil on platelet aggregation and thromboxane synthesis. 1985 Thromb. Res. pmid:2986312
Lai LJ et al. Trilinolein inhibits epinephrine-induced human platelet aggregation. 1994 Thromb. Res. pmid:7863478
Wu TM et al. Inhibitory effect of hexapeptide (RGRHGD) on platelet aggregation. 2000 Thromb. Res. pmid:10674405
Leoncini G et al. In retinal vein occlusion platelet response to thrombin is increased. 2009 Thromb. Res. pmid:19660790
Perneby C et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. 1999 Thromb. Res. pmid:10632465
Schorer AE and White JG Interleukin 1 enhances arterial thrombogenicity in vitro. 1989 Thromb. Res. pmid:2609290
Udvardy M et al. Altered primary haemostasis in Conn's syndrome. 1992 Thromb. Res. pmid:1448795
Altman R et al. Why single daily dose of aspirin may not prevent platelet aggregation. 1988 Thromb. Res. pmid:3140408
De la Cruz JP et al. Effect of erythrocytes and prostacyclin production in the effect of fructose and sorbitol on platelet activation in human whole blood in vitro. 1997 Thromb. Res. pmid:9219331
Lukaszyk A et al. Does acute experimental pancreatitis affect blood platelet function? 1989 Thromb. Res. pmid:2524119
Delvos U et al. Direct radioimmunological measurement of thromboxane B2 in plasma. 1985 Thromb. Res. pmid:4082109
Swart SS et al. Functional significance of the platelet alpha2-adrenoceptor: studies in patients with myeloproliferative disorders. 1984 Thromb. Res. pmid:6326344
Alessandrini P et al. Physiologic variables affecting thromboxane B2 production in human whole blood. 1985 Thromb. Res. pmid:3983893
Wallis RB Mechanisms of action of sulphinpyrazone. 1983 Thromb. Res. Suppl. pmid:6415857
Perkett EA et al. Lymphocyte and granulocyte migration across the endothelial layer of bovine pulmonary artery intimal explants towards lymphocyte conditioned medium. 1986 Tissue Cell pmid:3810636
Nakazawa I et al. Some features of the metastatic cancer cells in prostaglandin production. 1989 Tohoku J. Exp. Med. pmid:2510366
Watanabe J et al. Effect of vitamin E on platelet aggregation in diabetes mellitus. 1984 Tohoku J. Exp. Med. pmid:6474447
Watanabe J et al. Effect of prostaglandin synthetase inhibitors on platelet aggregation and thromboxane production in diabetes mellitus. 1984 Tohoku J. Exp. Med. pmid:6515648
Nakazawa I et al. Some features in prostaglandin synthesis of the cancer cells which metastasized into liver from intestinal cancer lesions. 1993 Tohoku J. Exp. Med. pmid:8266326
Tomita Y et al. Leukotrienes and thromboxane B2 stimulate normal human melanocytes in vitro: possible inducers of postinflammatory pigmentation. 1988 Tohoku J. Exp. Med. pmid:3252558
Santostefano MJ et al. Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody. 2012 Toxicol Pathol pmid:22552394
McKinnon KP et al. In vitro ozone exposure increases release of arachidonic acid products from a human bronchial epithelial cell line. 1993 Toxicol. Appl. Pharmacol. pmid:8442000
Carpenter LJ and Roth RA Involvement of thromboxane in injury to isolated rat lungs perfused with phorbol myristate acetate in the presence and absence of neutrophils. 1987 Toxicol. Appl. Pharmacol. pmid:3672516
Sahota T et al. Model-based analysis of thromboxane Bâ‚‚ and prostaglandin Eâ‚‚ as biomarkers in the safety evaluation of naproxen. 2014 Toxicol. Appl. Pharmacol. pmid:24667227
Eisenmann CJ and Miller RK The effect of selenium compounds (selenite, selenate, ebselen) on the production of thromboxane and prostacyclin by the human term placenta in vitro. 1995 Toxicol. Appl. Pharmacol. pmid:7482536
Fujimoto Y et al. Effects of endocrine disruptors on arachidonic acid metabolism in rabbit platelets. 2003 Toxicol. Appl. Pharmacol. pmid:12781627
Ganey PE and Roth RA 5-Hydroxytryptamine and thromboxane in platelets from rats treated with monocrotaline pyrrole. 1987 Toxicol. Appl. Pharmacol. pmid:3564035
Miller PD et al. Effect of ozone exposure on lung functions and plasma prostaglandin and thromboxane concentrations in guinea pigs. 1987 Toxicol. Appl. Pharmacol. pmid:3470978
Yarom R et al. The effect of T-2 toxin on human platelets. 1984 Toxicol. Appl. Pharmacol. pmid:6710522
Leung LK and Glauert HP Reduction of the concentrations of prostaglandins E2 and F2alpha, and thromboxane B2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate. 1996 Toxicol. Lett. pmid:8644126
Ferrari D et al. Cyanidin-3-O-glucoside inhibits NF-kB signalling in intestinal epithelial cells exposed to TNF-α and exerts protective effects via Nrf2 pathway activation. 2016 Toxicol. Lett. pmid:27793764
Ren R et al. Protective effects of Danshensu on liver injury induced by omethoate in rats. 2010 Toxicol. Mech. Methods pmid:20843270
Mayer AM et al. Cyanobacterial Microcystis aeruginosa lipopolysaccharide elicits release of superoxide anion, thromboxane Bâ‚‚, cytokines, chemokines, and matrix metalloproteinase-9 by rat microglia. 2011 Toxicol. Sci. pmid:21362633
Mayer AM et al. Classical and Alternative Activation of Cyanobacterium Oscillatoria sp. Lipopolysaccharide-Treated Rat Microglia in vitro. 2016 Toxicol. Sci. pmid:26609141
Chan CP et al. Inhibition of cyclooxygenase activity, platelet aggregation and thromboxane B2 production by two environmental toxicants: m- and o-cresol. 2005 Toxicology pmid:15664436
Song YM et al. Effects of scorpion venom bioactive polypolypeptides on platelet aggregation and thrombosis and plasma 6-keto-PG F1alpha and TXB2 in rabbits and rats. 2005 Toxicon pmid:15975616
Huang HC Release of slow reacting substance from the guinea-pig lung by phospholipases A2 of Vipera russelli snake venom. 1984 Toxicon pmid:6206608
Al-Hassan JM et al. Vasoconstrictor components in the Arabian Gulf catfish (Arius thalassinus, Ruppell) proteinaceous skin secretion. 1986 Toxicon pmid:3824400
Zapol WM et al. Plasma thromboxane and prostacyclin metabolites in sheep partial cardiopulmonary bypass. 1980 Trans Am Soc Artif Intern Organs pmid:7018060
Westenfelder C et al. Renal function in calves with total artificial hearts. 1985 Trans Am Soc Artif Intern Organs pmid:3837477
Wonders TR et al. Reduced plasma thromboxane elevation during partial cardiopulmonary bypass in thrombocytopenic sheep. 1981 Trans Am Soc Artif Intern Organs pmid:7331082
Bito LZ Prostaglandins and other eicosanoids: their ocular transport, pharmacokinetics, and therapeutic effects. 1986 Trans Ophthalmol Soc U K pmid:3541303
Güllner HG et al. Correction of increased prostacyclin production in Bartter's syndrome by indomethacin. 1980 Trans. Assoc. Am. Physicians pmid:7018063
Di Minno G et al. In vivo platelet activation in homozygous cystathionine beta-synthase deficiency: a probucol-sensitive phenomenon. 1992 Trans. Assoc. Am. Physicians pmid:1308991
Tobian L et al. Prostaglandin alterations in barely hypertensive Dahl S rats. 1985 Trans. Assoc. Am. Physicians pmid:3842205
Menitove JE et al. Use of prostacyclin to inhibit activation of platelets during preparation of platelet concentrates. 1984 Nov-Dec Transfusion pmid:6390814